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Abstract
Purpose While the symptoms of narcolepsy are often
amenable to treatment with sodium oxybate (SXB), the
respiratory effects of long-term SXB treatment have not
been systematically studied. Recent reports have implicated
SXB with several cases of worsening sleep-related breath-
ing disturbances and accidental death. In addition, these
patients are at risk for obesity, which may aggravate co-
morbid obstructive sleep apnea.
Methods Based on a review of the literature and the clinical
experience of the author, recommendations for the use of
SXB in patients with sleep-disordered breathing have been
developed.
Results Among narcolepsy patients with evidence of sleep
disordered breathing during baseline polysomnography,
SXB should be prescribed only to those patients who fully
comply with nasal continuous positive airway pressure
therapy. The respiratory status of other SXB-treated patients
should be periodically evaluated with nocturnal oximetry.
Conclusions Based on the currently available data, physi-
cians prescribing SXB should remain vigilant for the
possible development of sleep-disordered breathing during
long-term treatment with SXB.
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Introduction
Narcolepsy is a life-long neurological disorder character-
ized by excessive daytime sleepiness, cataplexy, and other
abnormal expressions of rapid eye movement sleep [1]. It is
now believed that the pathophysiology of narcolepsy
involves the absence of a fully functional hypocretin
signaling system [1]. In addition to frequent awakenings
and abnormal REM sleep, the nocturnal sleep of narcolepsy
is often further disrupted by obstructive sleep apnea (OSA)
which is more common in these patients [2–4]. Additional
evidence suggests that the lack of hypocretin predisposes
this population to obesity [5–7] which also occurs with
significantly greater frequency among patients with narco-
lepsy. These patients are at risk for further weight gain even
after treatment is initiated [8], making OSA more likely to
occur over time.
The symptoms of cataplexy and excessive daytime
sleepiness are often amenable to treatment with sodium
oxybate (SXB) [9]. Based on the results of several level 1
studies [10], SXB is recognized as an effective treatment of
cataplexy, daytime sleepiness, and disrupted sleep due to
narcolepsy [11]; however, SXB is a central nervous system
and respiratory depressant, and these safety issues are
described in the product labeling, which includes a black
box warning [12].
The use of other central nervous system (CNS) depres-
sants, such as ethanol, has been associated with worsening
sleep apnea symptoms [13, 14], and these concerns have
recently been extended to include SXB. One recent report
described the worsening of sleep-related breathing distur-
bances during polysomnography in two SXB-treated
narcolepsy patients with OSA. One was a 60-year-old
woman [body mass index (BMI), 26] who demonstrated an
apnea–hypopnea index (AHI) of 8/h and 10/h during two
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consecutive nights while taking SXB. These decreased to
3/h and 6/h when SXB was discontinued. The other patient
was a 58-year-old man (BMI, 32) whose AHI increased
from 5/h and 11/h on two consecutive nights to 24/h and
45/h following the administration of SXB. Following the
initiation of nasal continuous positive airway pressure
(CPAP), the AHI improved to 1/h and 3/h. Although these
authors suggest that the use of SXB therapy should be
initiated in the sleep lab, this precautionary measure cannot
predict which patients may develop sleep-disordered
breathing with prolonged exposure [15].
Other reports have implicated the use of SXB with fatal
outcomes. One report described a 53-year-old woman with
sleep apnea who was receiving treatment with nightly SXB
for narcolepsy. Concomitant medications included trama-
dol, gabapentin, cetirizine, modafinil, and carisoprodol. In
this case, the combined use of SXB with other CNS
depressants was felt to be a contributing factor in her death
[16]. Another report also described three deaths associated
with the use of SXB. One was clearly an intentional
overdose; however, the other two were unexpected deaths
than occurred during sleep. One patient was also taking
zolpidem and the other was taking alprazolam and
quetiapine and was not wearing his CPAP mask [17].
Although the actual cause of death is not known with
certainty in all of these cases [18], they raise safety
concerns about SXB to a level that requires proactive
monitoring of all patients on SXB for the possible
development of respiratory depression. An extensive review
of post-marketing adverse events associated with SXB
including other fatalities is currently in press [19].
To date, only one randomized, placebo-controlled trial
has evaluated the use of SXB in patients with OSA. In that
study, the use of SXB was associated with statistically but
not clinically significant improvements in the AHI of some
patients. Three patients experienced clinically significant
decreases in arterial oxygen saturation to approximately
55%. In two patients, this decrease was for a brief duration,
and they continued SXB treatment without further incident
while the third was withdrawn from the trial [20]. Thus,
while the use of SXB may slightly improve the AHI in most
patients, it appears there may be a subset of patients that are
more susceptible to the respiratory depressant effects of
SXB. It addition, patient exposure to SXB in this study was
limited to 2 weeks. The respiratory effects of long-term SXB
treatment have not been systematically studied.
Based on the limited amount of available information, it
is clear that a systematic study of the long-term exposure to
SXB and patient risk of developing OSA should be
undertaken. In the meantime, however, the clinician must
take the initiative to carefully monitor these patients for the
possible development of worsening sleep-disordered
breathing. Obese patients are at significantly greater risk
for OSA and need to be aggressively monitored. Each
clinician should develop their own standard operating
procedure for prescribing SXB to their patients. As a
guideline, the author uses the following parameters when
prescribing SXB to patients with narcolepsy.
Baseline polysomnography is generally performed in
most patients with narcolepsy. If sleep-disordered breathing
is present, then SXB should only be prescribed for patients
who are fully compliant with nasal CPAP therapy. Although
not studied systematically, the author's experience suggests
that SXB may improve CPAP compliance in patients with
narcolepsy due to improved sleep maintenance. Therefore,
the use of SXB should not necessarily be limited to the
treatment of narcolepsy patients with only mild OSA;
however, patients should be instructed not to take SXB if
they do not wear their CPAP mask.
If OSA is not present at baseline, then patients should be
followed with nocturnal oximetry as follows:
& Every 2 years for all SXB-treated patients
& Annually for obese patients (BMI, >30)
& Following a 15-lb (6.8 kg) gain in body weight
& Following an increase in visual analog snoring severity
scale score (see Fig. 1)
& When starting a newly prescribed sedating medication
which may worsen OSA.
Although there are no available data on the effect of SXB
on CPAP pressure requirements, patients on CPAP who are
taking SXB should also have periodic oximetric testing. It
is the author's opinion that worsening Epworth Sleepiness
Scale scores alone should not be used as an indication of
the development of OSA in patients taking SXB.
If nocturnal oximetric monitoring on or off nasal CPAP
reveals a saw-tooth pattern of oxygen desaturation, patients
taking SXB should undergo further evaluation with
Evaluation of snoring as reported by bed partner (circle a number): 
1 2 3 4 5 6 7 8 9 10
0-3 Occasional soft snoring, not bothersome to bed partner 
4-6 Persistent snoring, bothersome to bed partner 
7-9 Persistent loud snoring, frequently annoying to bed partner 
 10 Heroic snoring, continuous loud snoring not tolerated by bed partner
Fig. 1 Snoring evaluation
questionnaire
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nocturnal polysomnography. The author has observed the
development of classic Cheyne–Stokes respiration or
periodic breathing in patients taking SXB. If a sustained
pattern of desaturation is documented, SXB should be
discontinued. Pulmonary function tests should be per-
formed, and a pulmonary consultation for these patients
should be considered.
The choice of therapeutic options for the treatment of
narcolepsy is limited and leaves many of these patients with
a poor quality of life [21]. SXB remains a valuable option
for a significant number of patients with narcolepsy.
Although the available data is limited, the author suggests
that patient safety requires continuing attention to the
possible development of sleep-disordered breathing during
long-term treatment with SXB.
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